文献速递血管炎

来氟米特治疗大血管炎的有效性与安全性:队列研究的系统评价与荟萃分析

Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
PubMed 文献 · Semin Arthritis Rheum · 2023-01-11

该系统评价与荟萃分析纳入评估来氟米特(LEF)治疗大动脉炎(TAK)的8项研究和巨细胞动脉炎(GCA)的7项研究,均为高偏倚风险的非对照观察性研究,证据确定性低或极低。TAK中至少部分缓解的合并比例为75%(95%CI 0.64-0.84),GCA中为60%(95%CI 0.17-0.95)。作者认为LEF耐受性良好,可能对TAK和GCA患者有效。

要点

  • TAK中LEF治疗后至少部分缓解的合并比例为75%(95%CI 0.64-0.84)。
  • GCA中LEF治疗后至少部分缓解的合并比例为60%(95%CI 0.17-0.95)。
  • 所有纳入研究均为高偏倚风险的非对照观察性研究,证据确定性低或极低。

核心结论

  • LEF耐受性良好,可能对TAK和GCA患者有效。

研究设计与样本

  • 系统评价与荟萃分析,检索评估LEF在大血管炎中疗效的研究,采用随机效应模型进行荟萃分析。
  • 文献检索识别出评估LEF治疗TAK的8项研究和治疗GCA的7项研究,均为非对照观察性研究。

主要发现

  • TAK中达到至少部分缓解的合并比例为75%(95%CI 0.64-0.84),血管造影稳定为86%(95%CI 0.77-0.94),复发为12%(95%CI 0.05-0.21)。
  • TAK中LEF治疗后泼尼松龙剂量平均减少量为15.7 mg/d(95%CI 10.28-21.16),不良事件发生率为8%(95%CI 0.02-0.16)。
  • GCA中达到至少部分缓解的合并比例为60%(95%CI 0.17-0.95),LEF治疗后泼尼松龙剂量平均减少量为15.63 mg/d(95%CI 1.29-32.55),53%的患者能够停用糖皮质激素(95%CI 0.25-0.80)。
  • GCA中复发为21%(95%CI 0.14-0.28),不良事件为28%(95%CI 0.12-0.46)。

关键数值与推荐

  • TAK中LEF与甲氨蝶呤(MTX)或环磷酰胺比较,在诱导缓解、预防复发和耐受性方面LEF更优。
  • TAK中LEF与托法替布比较,两药疗效相当。
  • GCA中LEF与MTX比较,疗效和耐受性相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有纳入研究均为非对照观察性研究,具有高偏倚风险,意味着证据确定性低或极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The search for new glucocorticoid-sparing disease-modifying anti-rheumatic drugs continues to be an unmet need in large vessel vasculitis (LVV). This report aims to assess the effectiveness and safety of leflunomide (LEF) in Takayasu arteritis (TA) and giant cell arteritis (GCA). METHODS: We systematically reviewed the literature, searching for studies evaluating the efficacy of LEF in LVV. A meta-analysis was conducted using the random-effects method. RESULTS: The literature search identified eight studies that assessed LEF in TAK and seven in GCA. All were uncontrolled observational studies with a high risk of bias, implying a low or very-low certainty of evidence. In TAK, the pooled proportion of patients achieving at least a partial remission was 75% (95% CI: 0.64-0.84), angiographic stabilization was observed in 86% (0.77-0.94) and relapses in 12% (0.05-0.21). The mean reduction in the prednisolone dose (MRPD) after LEF treatment was 15.7 mg/d (10.28-21.16). Adverse events were observed in 8% of patients (0.02-0.16). Comparison of LEF with methotrexate (MTX) or cyclophosphamide revealed LEF to be superior in terms of remission induction, relapse prevention, and tolerance. When compared with tofacitinib, both drugs demonstrated comparable efficacy. In GCA, the pooled proportion of patients achieving at least a partial remission was 60% (0.17-0.95). The MRPD after LEF treatment was 15.63 mg/d (1.29-32.55) and 53% of the patients were able to discontinue glucocorticoids (0.25 - 0.80). Relapses were observed in 21% of cases (0.14- 0.28) and adverse events in 28% (0.12-0.46). Comparison of LEF with MTX showed similar efficacy and tolerance. CONCLUSION: LEF is well tolerated and might be effective for patients with TAK and GCA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Narváez J, Estrada P, LLop D, et al. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies. Semin Arthritis Rheum. 2023. PMID: 36645992. doi:10.1016/j.semarthrit.2023.152166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。